SCHEMBL4607544

SCHEMBL4607544

CCS(=O)(=O)c1cc(C)c2nnc(C(N)=O)c(Nc3cncc(Cl)c3)c2c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 7/20 0.37
CSF1R P07333 2/20 0.34
LRRK2 Q5S007 4/20 0.33
TP53 P04637 1/20 0.33
TDO2 P48775 1/20 0.32
SYK P43405 1/20 0.32
AURKA O14965 2/20 0.32
PLK4 O00444 1/20 0.32
ROCK2 O75116 1/20 0.32
CHEK2 O96017 1/20 0.32
PIM1 P11309 1/20 0.32
CDK2 P24941 1/20 0.32
FLT4 P35916 1/20 0.32
KDR P35968 1/20 0.32
MAPK8 P45983 1/20 0.32
MAPK9 P45984 1/20 0.32
CSNK1D P48730 1/20 0.32
GSK3A P49840 1/20 0.32
GSK3B P49841 1/20 0.32
LIMK1 P53667 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4607293 0.90 PDE4B (0.46) PDE4BCSF1RLRRK2
SCHEMBL4608222 0.89 PDE4B (0.39) PDE4BCSF1RLRRK2AURKAPLK4
SCHEMBL4608384 0.86 PDE4B (0.47) PDE4BCSF1RLRRK2AURKAPLK4
SCHEMBL2509132 0.85 PDE4B (0.53) PDE4BCSF1RTP53THRB
SCHEMBL4608176 0.83 PDE4B (0.45) PDE4BCSF1RLRRK2
SCHEMBL8238030 0.83 TDO2 (0.34) CSF1RTP53TDO2SYKLIMK1
Hydrochloric Acid SCHEMBL4607073 0.82 TDO2 (0.34) TP53TDO2SYKLIMK1
SCHEMBL4649873 0.81 SLC2A1 (0.37) PDE4BCSF1RLRRK2TP53TDO2
SCHEMBL4605922 0.80 PDE4B (0.35) PDE4BCSF1RLRRK2AURKAPLK4
SCHEMBL2477404 0.79 PDE4B (0.51) PDE4BCSF1RTP53THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080280911-A1 Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) GLAXO GROUP LIMITED (GB) 2008-11-13 US claimed
EP-1945616-A1 CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) GLAXO GROUP LIMITED (GB) 2008-07-23 EP claimed
WO-2007045861-A1 CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) GLAXO GROUP LIMITED (GB) 2007-04-26 WO claimed
US-20080280911-A1 Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) GLAXO GROUP LIMITED (GB) 2008-11-13 US disclosed
US-20080280911-A1 Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) GLAXO GROUP LIMITED (GB) 2008-11-13 US disclosed
EP-1945616-A1 CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) GLAXO GROUP LIMITED (GB) 2008-07-23 EP disclosed
WO-2007045861-A1 CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) GLAXO GROUP LIMITED (GB) 2007-04-26 WO disclosed
WO-2007045861-A1 CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) GLAXO GROUP LIMITED (GB) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280911-A1 Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) PDE4A, PDE4B, PDE3B PDE4B 2/4885CSF1R 3778/4885LRRK2 2855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.